



(11) **EP 1 070 725 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims 7
- (48) Corrigendum issued on:
23.02.2011 Bulletin 2011/08
- (45) Date of publication and mention of the grant of the patent:
01.09.2010 Bulletin 2010/35
- (21) Application number: **99916044.3**
- (22) Date of filing: **09.04.1999**
- (51) Int Cl.:
A61K 9/14 (2006.01) A61K 31/70 (2006.01)
- (86) International application number:
PCT/JP1999/001907
- (87) International publication number:
WO 1999/052931 (21.10.1999 Gazette 1999/42)

(54) **SOLID DISPERSION CONTAINING SIALIC ACID DERIVATIVE**
SIALSÄURE-DERIVATE ENTHALTENDE FESTE DISPERSION
DISPERSION SOLIDE CONTENANT UN DERIVE D'ACIDE SIALIQUE

- | | |
|--|---|
| <p>(84) Designated Contracting States: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE</p> <p>(30) Priority: 10.04.1998 JP 9889998</p> <p>(43) Date of publication of application: 24.01.2001 Bulletin 2001/04</p> <p>(73) Proprietor: Mitsubishi Chemical Corporation Minato-ku Tokyo 108-0014 (JP)</p> <p>(72) Inventors: • INAMORI, Takeshi; Mitsubishi Chem.Corp. Kashima-gun, Ibaraki 314-0255 (JP) • TAKAHASHI, Chikako; Mitsubishi Chem.Corp. Kashima-gun, Ibaraki 314-0255 (JP)</p> | <p>• FUJIMURA, Yoshiyuki; Mitsubishi Chem.Corp. Yokohama-shi, Kanagawa 227-8502 (JP)</p> <p>(74) Representative: Polypatent Postfach 40 02 43 51410 Bergisch Gladbach (DE)</p> <p>(56) References cited: EP-A- 0 267 297 JP-A- 9 002 957 JP-A- 62 209 094 JP-A- 63 063 697</p> <p>• WIN LUNG CHIOU ET AL: "PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS" JOURNAL OF PHARMACEUTICAL SCIENCE,, vol. 60, no. 9, 1 September 1971 (1971-09-01), pages 1281-1302, XP009027674 ISSN: 0022-3549</p> |
|--|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 070 725 B9

Description

Technical Field

5 **[0001]** The present invention relates to a solid dispersion containing a substance useful for therapeutic and/or preventive treatment of various diseases resulting from impairment of cholinergic nerve cells, and a pharmaceutical composition containing said solid dispersion.

Background Art

10 **[0002]** In order to utilize hardly soluble and/or hardly absorbable substances as a pharmaceutical preparation, it has been attempted to improve their solubility and absorbability. As a physicochemical method for such attempt, amorphization is known. In this technique, crystalline structures of the substances are destroyed and pulverized into a size of molecular level. An example of amorphized states includes solid dispersion. The solid dispersion contains a substance dispersed in a size of molecular level in a carrier, and the dispersion is such a state that a solid is dissolved in a solid. In the solid dispersion, a dispersed substance does not contact with each other, and accordingly, crystallization hardly occurs and stability of the substance in the amorphized state is generally improved.

15 **[0003]** It is known that solubility and absorbability of a hardly soluble compound can be improved by dispersing the substance in a water-soluble macromolecule to form an amorphous solid dispersion. For example, Japanese Patent Unexamined Publication (Kokai) 58-77811/1983 discloses that solubility and absorbability of nifedipine, which is useful as a therapeutic drug for angina pectoris, can be improved by dispersing said drug in hydroxypropylmethylcellulose to form a solid dispersion. As methods for preparing a solid dispersion, there are known, for example, the solvent method wherein a substance and a water-soluble macromolecule are dissolved in a suitable solvent, and then the solvent is removed (Chem. Pharm. Bull., 34 (8), 3408 (1986)), the fusion method wherein a substance and a water-soluble macromolecule are fused and solidified by cooling (J. Pharm. Sci., 59, 937 (1970)), the mixed grinding method wherein a substance and a water-soluble macromolecule are mixed and pulverized by a ball mill or the like (Yakuzaigaku (Pharmaceutics), 45 (4), 291 (1985)), the spray drying method wherein a solution of a drug and a water-soluble macromolecule is spray-dried (Chem. Pharm. Bull., 44 (3), 568 (1996)) and the like.

20 **[0004]** Gangliosides, which are glycosphingolipids including sialic acid, are components of biomembranes and abundantly contained in brains of higher animals. Variety of functions of gangliosides have recently been reported. Since gangliosides are present highly locally in membranes of the nerve system, their role in the nerve system have been focused. Sialic acid is an important component of gangliosides, and various sialic acid derivatives have been synthesized to investigate correlation between sialic acid and the functions of gangliosides and from a viewpoint of clinical applications (Japanese Patent Unexamined Publication Nos. 55-89298/1980, 61-243096/1986, 61-282390/1986, 63-41492/1988, 63-41494/1988, 63-63697/1988, 63-68526/1988, 64-52794/1989, 1-190693/1989, 3-151398/1991, WO93/10134, WO94/03469 etc.). Some reports have also been made on the activity of sialic acid derivatives (Japanese Patent Unexamined Publication Nos. 62-265229/1987, 1-93529/1989, 3-77898/1991, 3-81287/1991, and Brain Research, 438, 277-285 (1988)).


25 **[0005]** The applicants of the present application discovered previously sialic acid derivatives having an activity for activating an acetylcholine synthetase, i.e., choline acetyltransferase (ChAT) (Japanese Patent Unexamined Publication No. 7-228592/1995). These sialic acid derivatives have actions of improving central nervous system disorders such as dysmnnesia in senile dementia including Alzheimer's disease and peripheral nerve system disorders such as diabetic neuropathy, and therefore they are very useful as active ingredients of drugs. Since the compounds of said invention activate ChAT activity in cholinergic nerve cells, their prophylactic or therapeutic efficacy for dementia, dysmnnesia and symptoms resulting therefrom is expected. Specifically, they are considered to be useful for prophylactic and therapeutic treatments of senile dementia including Alzheimer's disease; cerebrovascular dementia accompanying apoplectic stroke, encephalorrhagy, cerebral infarction etc.; and dysmnnesia, hypoprosexia, allophasis, hypobulia, emotional disorder, hallucination, paranoid state, behavioral abnormality and the like resulting from head injury, postencephalitis, cerebral paralysis, Huntington disease, Pick's disease, Down's syndrome, Parkinson's disease etc. They are also useful for prophylactic and therapeutic treatments of tardive dyskinesia; glaucoma; dysgryphia; peripheral nerve disorders of motor nerve, sensory nerve, autonomic nerve etc. including traumatological and inflammatory neuropathies; alcoholic nerve disorder, drug induced nerve disorder caused by carcinostatic agents etc., metabolic nerve disorder resulting from diabetes mellitus etc. or idiopathic peripheral nerve disorder induced by carcinostatic agents etc.; facial nerve palsy; ischiadic nerve palsy; myelopathic muscular atrophy; muscular dystrophy; myasthenia gravis; multiple sclerosis; amyotrophic lateral sclerosis; acute disseminated encephalomyelitis; Guillain-Barre syndrome; postvaccinal encephalitis; subacute myelo-optic neuropathy (SMON disease) and the like. However, these sialic acid derivatives are almost insoluble in water and hardly absorbable, and for this reason, drugs prepared by ordinary formulation techniques fail to sufficiently exert efficacy.

Disclosure of the Invention


[0006] An object of the present invention is to provide medicaments which comprise a sialic acid derivatives disclosed in Japanese Patent Unexamined Publication No. 7-228592/1995 and can sufficiently take sufficient effects. More specifically, the object of the present invention is to provide medicaments which achieve superior solubility and absorbability of the sialic acid derivative.

[0007] The inventors of the present invention made extensive studies to achieve the foregoing object. As a result, they found that the object was achievable by preparing a solid dispersion in which an active ingredient such as the aforementioned sialic acid derivatives or salts thereof in a water-soluble macromolecule, and that medicaments superior in solubility and absorbability of the active ingredient and capable of exerting high efficacy were successfully provided. The present invention was accomplished on the basis of these findings.

[0008] The present invention thus provides a solid dispersion which comprises a water-soluble macromolecule and a substance dispersed in the water-soluble macromolecule, wherein said substance is selected from the group consisting of a sialic acid derivative represented by the following general formula (I) and a salt thereof, and a hydrate thereof and a solvate thereof:




[in the above general formula (I), R¹ represents a steroid compound residue, R² represents hydrogen atom or a C₁-C₄ alkyl group, R³ represents a C₁-C₁₅ alkyl group,




{in the formula, R⁶ and R⁷ independently represent hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, hydroxyl group, R⁸O- (in the formula, R⁸ represents a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group), nitro group, amino group, a C₁-C₄ alkylamino group, a C₂-C₈ dialkylamino group or R⁹O-CO- (in the formula, R⁹ represents hydrogen atom, a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group), and symbol "L" represents an integer of from 0 to 6}, R¹⁰O(CH₂)_m- (in the formula, R¹⁰ represents hydrogen atom; a C₁-C₄ alkyl group; a phenyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; or a phenyl-(C₁-C₃) alkyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and carboxyl group, and symbol "m" represents an integer of from 2 to 6), or (R¹¹)(R¹²)N-(CH₂)_n- {in the formula, R¹¹ represents hydrogen atom or a C₁-C₄ alkyl group, R¹² represents hydrogen atom; a C₁-C₄ alkyl group; a C₂-C₇ acyl group; a C₁-C₄ alkylsulfonyl group; a phenylsulfonyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; or R¹³O-CO- (in the formula, R¹³ represents a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group) and symbol "n" represents an integer of from 2 to 6}, R⁴ represents hydrogen atom or a C₂-C₇ acyl group, R⁵ represents R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom or a C₂-C₇ acyl group) or R¹⁵NH- {in the formula, R¹⁵ represents a C₂-C₇ acyl group; R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom, a C₁-C₆ alkyl group, phenyl group, or a phenyl-(C₁-C₃) alkyl group, and p represents an integer of from 0 to 4); a C₇-C₁₁ aroyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; a phenyl-(C₁-C₃) alkylcarbonyl group

which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; a C₁-C₄ alkylsulfonyl group; or a phenylsulfonyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group}, and X represents an oxygen atom or a sulfur atom].


5 [0009] As preferred embodiments of the present invention, there are provided the aforementioned solid dispersion wherein R¹ represents



20 (in the formula, ---- represents a single bond or a double bond); the aforementioned solid dispersion, wherein R¹ represents




35 and the aforementioned solid dispersion, wherein R¹ represents




50 in the sialic acid derivative and a salt thereof, and a hydrate thereof and a solvate thereof. As other preferred embodiments of the present invention, there are provided the aforementioned solid dispersion wherein, as for the substance selected from the sialic acid derivative and a salt thereof, and a hydrate thereof and a solvate thereof, R² represents hydrogen atom or methyl group; the aforementioned solid dispersion, wherein R² represents hydrogen atom; the aforementioned solid dispersion, wherein R³ represents a C₁-C₈ alkyl group,

55



10 {in the formula, R⁶ and R⁷ independently represent hydrogen atom, a halogen atom, or R⁹O-CO- (in the formula, R⁹ represents hydrogen atom or a C₁-C₄ alkyl group), and symbol "L" represents an integer of from 0 to 3}, R¹⁰O(CH₂)_m- (in the formula, R¹⁰ represents hydrogen atom, a C₁-C₄ alkyl group, phenyl group, or a phenyl-(C₁-C₃) alkyl group, and symbol "m" represents an integer of from 2 to 4), or (R¹¹)(R¹²)N-(CH₂)_n- {in the formula, R¹¹ represents hydrogen atom, R¹² represents hydrogen atom, a C₂-C₇ acyl group, a C₁-C₄ alkylsulfonyl group or R¹³O-CO- (in the formula, R¹³ represents a phenyl-(C₁-C₃) alkyl group) and symbol "n" represents an integer of from 2 to 4}; and the aforementioned solid dispersion, wherein R³ represents a C₁-C₈ alkyl group or



(in the formula, symbol "L" represents an integer of from 0 to 3).

25 **[0010]** As further preferred embodiments of the present invention, as for the substance selected from the sialic acid derivative and a salt thereof, and a hydrate thereof and a solvate thereof, there are provided the aforementioned solid dispersion, wherein R³ represents a C₁-C₃ alkyl group; the aforementioned solid dispersion, wherein R⁴ represents hydrogen atom or acetyl group; the aforementioned solid dispersion, wherein R⁴ represents hydrogen atom; the aforementioned solid dispersion, wherein R⁵ represents R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom or acetyl group) or R¹⁵NH- {in the formula, R¹⁵ represents a C₂-C₇ acyl group, R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom, a C₁-C₄ alkyl group or a phenyl-(C₁-C₃) alkyl group, and symbol "p" represents an integer of from 0 to 4), a C₇-C₁₁ aroyl group, a C₁-C₃ alkylsulfonyl group or a phenylsulfonyl group}; the aforementioned solid dispersion, wherein R⁵ represents R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom) or R¹⁵NH- {in the formula, R¹⁵ represents a C₂-C₅ acyl group, R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom and symbol "p" represents 1)}; the aforementioned solid dispersion, wherein R⁵ represents R¹⁵NH- (in the formula, R¹⁵ represents acetyl group); and the aforementioned solid dispersion, wherein X represents oxygen atom.

35 **[0011]** As particularly preferred embodiments, there are provided the aforementioned solid dispersion, wherein the sialic acid derivative is 3 α -[N-(5-acetamido-3,5-dideoxy-2-O-methyl-α -D-glycero-D-galacto-2-nonulo pyranosonyl) amino]cholestane; the aforementioned solid dispersion, which comprises the aforementioned substance in substantially amorphous state; and the aforementioned solid dispersion, which does not substantially comprise said substance in crystallized state. As another aspect, there is provided a pharmaceutical composition comprising the aforementioned solid dispersion and a pharmaceutically acceptable carrier.

Brief Explanation of the Drawings

45 **[0012]**

50 Fig. 1 shows results of a dissolution test of a solid dispersion of the present invention. The results shown in the figure are averages of experiments performed in triplicate. The line with ■ represents the results obtained from a solid dispersion of the present invention (Example 1); and the line with □ from the solid powder of Comparative Example 1.

55 Fig. 2 shows results of an absorption test (rat) of a solid dispersion of the present invention. The results shown in the figure are averages of experiments performed in triplicate. The line with ■ represents the results obtained from a solid dispersion of the present invention (Example 2); and the line with □ from the suspension of Comparative Example 2.

Fig. 3 shows results of an absorption test (dog) of solid dispersions of the present invention. The results shown in the figure are averages of experiments performed in triplicate. The line with ■ represents the results obtained from a solid dispersion of the present invention (Example 3); the line with ♦ from a solid dispersion of the present invention


(Example 4), the line with ● from a solid dispersion of the present invention (Example 5), and line with □ from the capsule (solid powder) of Comparative Example 3.

Best Mode for Carrying out the Inventing

5
 [0013] The sialic acid derivative contained in the solid dispersion of the present invention is represented by the aforementioned general formula (I). Examples of the C₁-C₄ alkyl group defined in the aforementioned general formula (I) include methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, t-butyl group and the like. Examples of the C₁-C₁₅ alkyl group include methyl group, ethyl group, n-propyl group, i-propyl group, n-butyl group, t-butyl group, n-pentyl group, n-hexyl group, n-heptyl group, n-octyl group, n-decyl group, n-pentadecyl group and the like. Examples of the C₁-C₆ alkyl group include those C₁-C₆ alkyl groups exemplified above for the C₁-C₁₅ alkyl group. Examples of the halogen atom include fluorine atom, chlorine atom, bromine atom and the like. Examples of the phenyl-(C₁-C₃) alkyl group include benzyl group, phenethyl group and the like. Examples of the C₂-C₇ acyl group include acetyl group, propionyl group, butyryl group, valeryl group, benzoyl group and the like. Examples of the C₁-C₄ alkylsulfonyl group include methylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group, n-butylsulfonyl group and the like.


10
 [0014] Further, examples of the C₁-C₄ alkylamino group include methylamino group, ethylamino group, butylamino group and the like. Examples of the C₂-C₈ dialkylamino group include dimethylamino group, diethylamino group, dibutylamino group and the like. Examples of the C₇-C₁₁ aroyl group include benzoyl group, toluoyl group, naphthoyl group and the like. Examples of the phenyl-(C₁-C₃) alkylcarbonyl group include benzylcarbonyl group, phenylethylcarbonyl group, phenylpropylcarbonyl group and the like.

15
 [0015] A specific example of the steroid compound residue defined by R¹ in the formula (I) includes a group represented by the following formula:




35 (in the formula, --- represents a single bond or a double bond, and the steric configuration in the 3-position of the steroid skeleton is in either α -configuration or β configuration).

[0016] A preferred example of R¹ include a steroid compound residue represented by the following formula:




50 [0017] R² is preferably hydrogen atom or a methyl group, and hydrogen atom is most preferred. R³ is preferably a C₁-C₈ alkyl group,

55



10 {in the formula, R⁶ and R⁷ independently represent hydrogen atom, a halogen atom or R⁹O-CO- (in the formula, R⁹ represents hydrogen atom or a C₁-C₄ alkyl group), and symbol "L" represents an integer of from 0 to 3}, R¹⁰O(CH₂)_m- (in the formula, R¹⁰ represents hydrogen atom, a C₁-C₄ alkyl group, phenyl group, or a phenyl-(C₁-C₃) alkyl group, and symbol "m" represents an integer of from 2 to 4), or (R¹¹)(R¹²)N-(CH₂)_n- {in the formula, R¹¹ represents hydrogen atom, R¹² represents hydrogen atom, a C₂-C₇ acyl group, a C₁-C₄ alkylsulfonyl group or R¹³O-CO- (in the formula, R¹³ represents a phenyl-(C₁-C₃) alkyl group) and symbol "n" represents an integer of from 2 to 4}, more preferably a C₁-C₈ alkyl group or



(in the formula, symbol "L" represents an integer of from 0 to 3), and a C₁-C₃ alkyl group is most preferred.

25 **[0018]** R⁴ is preferably hydrogen atom or acetyl group, and hydrogen atom is most preferred. R⁵ is preferably R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom or acetyl group) or R¹⁵NH- {in the formula, R¹⁵ represents a C₂-C₅ acyl group, R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom, a C₁-C₄ alkyl group, or a phenyl-(C₁-C₃) alkyl group, and symbol "p" represents an integer of from 0 to 4), a C₇-C₁₁ aroyl group, a C₁-C₄ alkylsulfonyl group, or a phenylsulfonyl group}}, more preferably R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom) or R¹⁵NH- {in the formula, R¹⁵ represents a C₂-C₅ acyl group, R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom, and symbol "p" represents 1)}, most preferably R¹⁵NH- (in the formula, R¹⁵ represents acetyl group). X is most preferably an oxygen atom.

30 **[0019]** Specific examples of the substituents defined in the aforementioned general formula (I) and specific examples of the sialic acid derivatives represented by the formula (I) are mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995. Other than the sialic acid derivatives having the substituents exemplified above, those specifically disclosed in Japanese Patent Unexamined Publication No. 7-228592/1995 are also preferably used for the solid dispersion of the present invention. However, the sialic acid derivatives which can be used for the solid dispersion of the present invention are not limited to those mentioned above, and it should be understood that any derivatives falling within the scope of the general formula (I) can be utilized.

35 **[0020]** Most preferred sialic acid derivatives include 3 α -[N-(3-deoxy-2-O-methyl-α -D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 367 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 5),

3 α -[N(3-deoxy-2-O-methyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]-5-cholestene (α -isomer of Compound No. 507 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 7),

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-methyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 4 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 1),

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-phenyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 19 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 1),

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-benzyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 21 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 1),

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-methyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]-5-cholestene (α -isomer of Compound No. 234 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 1),

3 α -[N-(5-acetamido-3,5-dideoxy-2-S-phenyl-2-thio-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 260 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 2),

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-methyl-β-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -isomer of Compound No. 268 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table 3), and

3 α -[N-(5-acetamido-3,5-dideoxy-2-O-benzyl- β -D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (α -
isomer of Compound No. 281 mentioned in Japanese Patent Unexamined Publication No. 7-228592/1995, Table
3). However, the sialic acid derivatives of the general formula (I) which can be used for the solid dispersion of the
present invention are not limited to these examples.

5 [0021] Examples of salts formed with the carboxyl groups of the compounds represented by the general formula (I)
include, for example, salts with alkali metals such as sodium or potassium, and salts with ammonia, organic amines
such as tris(hydroxymethyl)aminomethane, N,N-bis(hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, eth-
anolamine, N-methylglucamine, and L-glucamine.

10 [0022] Examples of salts formed with the compounds represented by the general formula (I) include, for example,
inorganic acid salts such as hydrochlorides, hydrobromides, hydroiodides, sulfates, and phosphates, and organic acid
salts such as oxalates, maleates, fumarates, lactates, malates, citrates, tartrates, benzoates, methanesulfonates and
camphorsulfonates. However, the salts which can be used for the solid dispersion of the present invention are not limited
to these examples, and any of physiologically acceptable salts can be utilized.

15 [0023] The compound of the aforementioned formula (I) or a salt thereof may exist in the forms of a hydrate or a
solvate, and therefore, the hydrate or the solvate can also be used for the manufacture of the solid dispersion of the
present invention.

Solvents for forming the solvates are not particularly limited, and include, for example, methanol, ethanol, isopropanol,
acetone, ethyl acetate, methylene chloride and the like. Further, the compounds of the aforementioned formula (I) have
one or more asymmetric carbon atoms, and many isomers thereof may exist. Any of such isomers can be used for the
manufacture of the solid dispersion of the present invention. The compounds falling within the aforementioned general
formula (I) can be produced according to the method described in Japanese Patent Unexamined Publication No.
7-228592/1995 or analogous methods.

20 [0024] The types of the water-soluble macromolecules used for the manufacture of the solid dispersion of the present
invention are not particularly limited, and any kinds of macromolecules may be used so long as they are pharmaceutically
acceptable. Examples include, for example, hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, poly-
vinylpyrrolidone, polyethylene glycol, polyvinyl alcohol and the like. Furthermore, macromolecules having pH-dependent
solubility may also be used, and examples include carboxymethylethylcellulose, hydroxypropylmethylcellulose phthalate,
hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, methacrylic acid copolymer and the like.
Where the water-soluble macromolecules form a salt, any salts may be used. Two or more of the water-soluble macro-
molecules can be used in combination. The amount of the water-soluble macromolecules is not particularly limited, and
may be appropriately chosen by those skilled in the art. For example, the amount may be 0.5 to 20 parts by weight,
preferably 1 to 7 parts by weight based on the aforementioned substance as an active ingredient.

25 [0025] Methods for manufacturing the solid dispersion of the present invention are not particularly limited, and any
methods that can be utilized as a method to prepare a solid dispersion may be applied. Specifically, examples include
the solvent method (Chem. Pharm. Bull., 34 (8), 348 (1986)), the fusion method (J. Pharm. Sci., 59, 937 (1970)), the
mixed grinding method (Yakuzaigaku, 45 (4), 291 (1985)), the spray drying method (Chem. Pharm. Bull., 44 (3), 568
(1996)) and the like. Among them, the solvent method is preferred. In the solid dispersion of the present invention, it is
desirable that a substance selected from the group consisting of the sialic acid derivative represented by the aforemen-
tioned formula (I) and a salt thereof, and a hydrate thereof and a solvate thereof is dispersed in the aforementioned
water-soluble macromolecule at the molecule level, and substantially loses crystalline property. Whether or not the
substance is dispersed substantially in an amorphous state can be easily determined by, for example, measuring powder
X ray diffraction of the solid dispersion.

30 [0026] When the solid dispersion of the present invention is manufactured by the solvent method, a substance selected
from the group consisting of the sialic acid derivative represented by the aforementioned formula (I) and a salt thereof,
and a hydrate thereof and a solvate thereof can be dissolved in a suitable solvent, and the solvent can be removed from
the solution by a suitable method. The types of the solvents are not particularly limited so long as they can dissolve the
aforementioned substance, and it is preferred to use an organic solvent having high volatility and low toxicity. For example,
ethanol, methanol, isopropanol, acetone and the like can be suitably used. Two or more of these solvents may be used
in combination.

35 [0027] Methods to remove the solvent from the solution containing the aforementioned substance as an active ingre-
dient and the water-soluble macromolecule dissolved therein are not particularly limited, and commonly used methods
such as distillation by heating and vacuum distillation can be applied. After a solvent is removed, dried residue can be
pulverized and sized by using a screen mill, hammer mill, jet mill or the like, and if necessary, the resulting product can
be subjected to secondary drying and further sizing to produce a solid dispersion of the present invention. The afore-
mentioned solution can also be spray-dried by using a spray dryer or the like, and the resulting product may optionally
be subjected to secondary drying and then further sizing to produce a solid dispersion. Drying conditions may vary
depending on a type of a water-soluble macromolecule, a solvent, or an apparatus be used, as well as to a type of the

aforementioned substance as the active ingredient. Generally, the drying can be performed under heating at 200°C and under ordinary pressure or high vacuum of 1 torr or less for several seconds to ten and several hours.

[0028] The solid dispersion of the present invention per se can be used as a medicament. Generally, however, a pharmaceutical formulation in the form of subitized granule, granule, tablet, capsule, dry syrup or the like may be prepared and subjected to administration. The pharmaceutical preparation can be manufactured by subjecting the aforementioned solid dispersion to ordinary formulation processes such as, for example, mixing, granulation, sizing, tablet compression, coating, capsule filling and the like utilizing pharmaceutical manufacturing apparatuses. If necessary, a pharmaceutical composition may be prepared by using one or more suitable pharmaceutical additives, and then the pharmaceutical composition may be formulated in the aforementioned formulations.

[0029] The pharmaceutical additives include, for example, excipients (e.g., lactose, mannitol, crystalline cellulose, corn starch, potato starch etc.), disintegrating agents (e.g., sodium carboxymethyl starch, carboxymethylcellulose calcium, croscarmellose sodium, polyvinylpyrrolidone, low substituted hydroxypropylcellulose, carboxymethylcellulose etc.), fluidization improving agents (e.g., light anhydrous silicic acid, hydrated silicon dioxide etc.), coloring agents (e.g., titanium oxide, yellow ferric oxide etc.), flavoring agents (e.g., tartaric acid, ascorbic acid, citric acid etc.), surface active agents (e.g., sodium laurylsulfate, polysorbate 80, polyethylene hydrogenated castor oil etc.), dispersing agents (e.g., crystalline cellulose, carboxyvinyl polymer etc.), lubricants (e.g., magnesium stearate etc.) and the like, and the amounts of these pharmaceutical additives can be suitably chosen by those skilled in the art. The pharmaceutical additives can be added during any one or more of the steps. For example, they may be added during the production of the solid dispersion, or during the steps of preparing the pharmaceutical preparation from the solid dispersion.

Examples

[0030] The present invention will be explained more specifically with reference to examples.

Example 1

[0031] 5 g of 3 α -[N-(5-Acetamido-3,5-dideoxy-2-O-methyl- α -D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane (hereinafter referred to as Compound A) and 15 g of hydroxypropylcellulose were dissolved in 2.5 liter of methanol and spray-dried at 140°C by using a spray dryer. The resulting solid was subjected to vacuum dehydration at 70°C for 6 hours using a vacuum desiccator, and sized through a 32# mesh sieve to obtain a solid dispersion.

Example 2

[0032] Compound A (1 g) and 5 g of polyvinylpyrrolidone were dissolved in 0.7 liter of ethanol. 0.3 g of light anhydrous silicic acid was then added to the solution and suspended, and then the solvent was removed by heating at 80°C with stirring. The resulting solid was ground by using a grinding mill, subjected to vacuum dehydration at 70°C for 6 hours, and sized through a 32# mesh sieve to obtain a solid dispersion. 3.78 g of polyvinylpyrrolidone was added to 1.26 g of this solid dispersion, and mixed in a conventional manner. The resulting mixture was suspended in 1000 ml of purified water to obtain a uniform suspension, of which concentration of Compound A was 1 mg/5 ml.

Example 3

[0033] Compound A (5 g) and 35 g of hydroxypropylcellulose were dissolved in 2.5 liter of methanol and spray-dried at 140°C by using a spray dryer. The resulting solid was subjected to vacuum dehydration at 70°C for 6 hours using a vacuum desiccator, and sized through a 32# mesh sieve to obtain a solid dispersion. This solid dispersion was dissolved in a 5% aqueous solution of sodium laurylsulfate to obtain a formulation in the form of a solution, of which concentration of Compound A was 5 mg/ml.

Example 4

[0034] Compound A (5 g) and 35 g of hydroxypropylcellulose were dissolved in 2.5 liter of methanol, and 20 g of polyvinylpyrrolidone was added and suspended in the solution. The suspension was then spray-dried at 140°C by using a spray dryer. The resulting solid was subjected to vacuum dehydration at 70°C for 6 hours using a vacuum desiccator, and sized through a 32# mesh sieve to obtain a solid dispersion. This solid dispersion was filled into a capsule to obtain a formulation in the form of a capsule containing 5 mg of Compound A.

Example 5

5 [0035] 12.0 g of the solid dispersion obtained in Example 4 was added with 6.06 g lactose, 5.6 g of sodium carboxymethyl starch, 4.2 g of hydrated silicon dioxide and 0.14 g of magnesium stearate, and the mixture was mixed and compressed into a tablet in a conventional manner to obtain a tablet containing 5 mg of Compound A.

Comparative Example 1

10 [0036] Compound A (5 g) and 15 g of hydroxypropylcellulose were mixed to obtain solid powder.

Comparative Example 2

15 [0037] Compound A (1 g), 5 g of polyvinylpyrrolidone and 0.3 g of light anhydrous silicic acid were mixed to obtain solid powder. 3.78 g of polyvinylpyrrolidone was added to 1.26 g of this solid powder, and mixed in a conventional manner. The resulting mixture was suspended in 1000 ml of purified water to obtain a uniform suspension, of which concentration of Compound A was 1 mg/5 ml.

Comparative Example 3

20 [0038] Compound A (5 g), 35 g of hydroxypropylcellulose and 20 g of polyvinylpyrrolidone were mixed to obtain solid powder. This solid powder was filled into a capsule to obtain a formulation in the form of a capsule containing 5 mg of Compound A.

Test Example 1

25 [0039] Residual solvent in each of the solid dispersions obtained in Examples 1, 2, 3 and 4 was measured by gas chromatography. As a result, the residual solvent in the solid dispersions obtained in Examples 1, 2, 3 and 4 was less than the detection limit (50 ppm).

30 Test Example 2

35 [0040] A dissolution test was performed for the solid dispersion and the solid powder obtained in Example 1 and Comparative Example 1, respectively. Each sample corresponding to 10 mg of Compound A was added to 100 ml of distilled water at 37°C with stirring using a stirrer, and the solution was sampled after a given period. The dissolution amount of Compound A in the sampled solution was quantified. The results are shown in Fig. 1. The solid dispersion of Example 1 was found to have more superior dissolution property compared with the solid powder of Comparative Example 1.

40 Test Example 3

45 [0041] Absorption tests were performed using rats for the suspensions obtained in Example 2 and Comparative Example 2. Compound A (1 mg/kg/5 ml of suspension) was forcibly administered to rats. Blood was collected after a given period, and plasma concentration of Compound A was quantified. The results are shown in Fig. 2. The suspension of the solid dispersion of Example 2 was found to have more superior absorption property compared with the suspension of the solid powder of Comparative Example 2.

Test Example 4

50 [0042] Absorption tests were performed using dogs for formulations obtained in Examples 3, 4, 5 and Comparative Example 3. Each formulation containing 5 mg of Compound A was forcibly administered to dogs. Blood was collected after a given period, and plasma concentration of Compound A was quantified. The results are shown in Fig. 3. The formulations of Examples 3, 4 and 5 were found to have more superior absorption properties compared with the capsule of Comparative Example 3.


55 Industrial Applicability

[0043] By using the solid dispersion of the present invention, solubility and absorbability of the sialic acid derivatives of the formula (I) and salts thereof, which have superior efficacy as medicaments, can be improved, and the problems


accompanied with conventional methods, i.e., residual solvent, decomposition, contamination of foreign substances and the like, can be eliminated.

5 Claims

1. A solid dispersion which comprises a water-soluble macromolecule and a substance dispersed in the water-soluble macromolecule, wherein said substance is selected from the group consisting of a sialic acid derivative represented by the following general formula (I) and a salt thereof, and a hydrate thereof and a solvate thereof:



[in the above general formula (I), R¹ represents a steroid compound residue, R² represents hydrogen atom or a C₁-C₄ alkyl group, R³ represents a C₁-C₁₅ alkyl group,




{in the formula, R⁶ and R⁷ independently represent hydrogen atom, a halogen atom, a C₁-C₄ alkyl group, hydroxyl group, R⁸O- (in the formula, R⁸ represents a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group), nitro group, amino group, a C₁-C₄ alkylamino group, a C₂-C₈ dialkylamino group or R⁹O-CO- (in the formula, R⁹ represents hydrogen atom, a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group), and symbol "L" represents an integer of from 0 to 6}, R¹⁰O(CH₂)_m- (in the formula, R¹⁰ represents hydrogen atom; a C₁-C₄ alkyl group; a phenyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; or a phenyl-(C₁-C₃) alkyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and carboxyl group, and symbol "m" represents an integer of from 2 to 6), or (R¹¹)(R¹²)N-(CH₂)_n- (in the formula, R¹¹ represents hydrogen atom or a C₁-C₄ alkyl group, R¹² represents hydrogen atom; a C₁-C₄ alkyl group; a C₂-C₇ acyl group; a C₁-C₄ alkylsulfonyl group; a phenylsulfonyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; or R¹³O-CO- (in the formula, R¹³ represents a C₁-C₄ alkyl group, phenyl group or a phenyl-(C₁-C₃) alkyl group) and symbol "n" represents an integer of from 2 to 6}, R⁴ represents hydrogen atom or a C₂-C₇ acyl group, R⁵ represents R¹⁴O- (in the formula, R¹⁴ represents hydrogen atom or a C₂-C₇ acyl group) or R¹⁵NH- (in the formula, R¹⁵ represents a C₂-C₇ acyl group; R¹⁶O(CH₂)_p-CO- (in the formula, R¹⁶ represents hydrogen atom, a C₁-C₆ alkyl group, phenyl group, or a phenyl-(C₁-C₃) alkyl group, and p represents an integer of from 0 to 4); a C₇-C₁₁ aroyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; a phenyl-(C₁-C₃) alkylcarbonyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group; a C₁-C₄ alkylsulfonyl group; or a phenylsulfonyl group which may have one or more substituents selected from the group consisting of a C₁-C₄ alkyl group, a halogen atom, hydroxyl group, nitro group, amino group, and a carboxyl group}, and X represents an oxygen atom or a sulfur atom].

2. The solid dispersion according to claim 1 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R¹ is:

5

10



15


(in the formula, ---- represents a single bond or a double bond) and a salt thereof, and a hydrate thereof and a solvate thereof.

3. The solid dispersion according to claim 1 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R¹ is:

20

25

30




and a salt thereof, and a hydrate thereof and a solvate thereof.

35

4. The solid dispersion according to claim 1 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R¹ is:

40

45



and a salt thereof, and a hydrate thereof and a solvate thereof.


50

5. The solid dispersion according to any one of claims 1 to 4 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R² is hydrogen atom or methyl group and a salt thereof, and a hydrate thereof and a solvate thereof.

55


6. The solid dispersion according to any one of claims 1 to 4 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R² is hydrogen atom and a salt thereof, and a hydrate thereof and a solvate thereof.

7. The solid dispersion according to any one of claims 1 to 6 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^3 is a C_1 - C_8 alkyl group,



{in the formula, R^6 and R^7 independently represent hydrogen atom, a halogen atom, or R^9O-CO- (in the formula, R^9 represents hydrogen atom or a C_1 - C_4 alkyl group), and symbol "L" represents an integer of from 0 to 3}, $R^{10}O(CH_2)_m-$ (in the formula, R^{10} represents hydrogen atom, a C_1 - C_4 alkyl group, phenyl group, or a phenyl- (C_1-C_3) alkyl group, and symbol "m" represents an integer of from 2 to 4), or $(R^{11})(R^{12})N-(CH_2)_n-$ (in the formula, R^{11} represents hydrogen atom, R^{12} represents hydrogen atom, a C_2 - C_7 acyl group, a C_1 - C_4 alkylsulfonyl group or $R^{13}O-CO-$ (in the formula, R^{13} represents a phenyl- (C_1-C_3) alkyl group) and symbol "n" represents an integer of from 2 to 4} and a salt thereof, and a hydrate thereof and a solvate thereof.

- 20 8. The solid dispersion according to any one of claims 1 to 6 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^3 is a C_1 - C_8 alkyl group or



(in the formula, symbol "L" represents an integer of from 0 to 3) and a salt thereof, and a hydrate thereof and a solvate thereof.

- 30 9. The solid dispersion according to any one of claims 1 to 6 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^3 is a C_1 - C_3 alkyl group and a salt thereof, and a hydrate thereof and a solvate thereof.

- 35 10. The solid dispersion according to any one of claims 1 to 9 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^4 is hydrogen atom or acetyl group and a salt thereof, and a hydrate thereof and a solvate thereof.

- 40 11. The solid dispersion according to any one of claims 1 to 9 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^4 is hydrogen atom and a salt thereof, and a hydrate thereof and a solvate thereof.

- 45 12. The solid dispersion according to any one of claims 1 to 11 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^5 is $R^{14}O-$ (in the formula, R^{14} represents hydrogen atom or acetyl group) or $R^{15}NH-$ {in the formula, R^{15} represents a C_2 - C_7 acyl group, $R^{16}O(CH_2)_p-CO-$ (in the formula, R^{16} represents hydrogen atom, a C_1 - C_4 alkyl group or a phenyl- (C_1-C_3) alkyl group, and symbol "p" represents an integer of from 0 to 4), a C_7 - C_{11} aroyl group, a C_1 - C_3 alkylsulfonyl group or a phenylsulfonyl group} and a salt thereof, and a hydrate thereof and a solvate thereof.


- 50 13. The solid dispersion according to any one of claims 1 to 11 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^5 is $R^{14}O-$ (in the formula, R^{14} represents hydrogen atom) or $R^{15}NH-$ {in the formula, R^{15} represents a C_2 - C_5 acyl group, $R^{16}O(CH_2)_p-CO-$ (in the formula, R^{16} represents hydrogen atom and symbol "p" represents 1)} and a salt thereof, and a hydrate thereof and a solvate thereof.

- 55 14. The solid dispersion according to any one of claims 1 to 11 which comprises the substance selected from the group consisting of the sialic acid derivative wherein R^5 is $R^{15}NH-$ (in the formula, R^{15} represents acetyl group) and a salt thereof, and a hydrate thereof and a solvate thereof.


15. The solid dispersion according to any one of claims 1 to 14 which comprises the substance selected from the group consisting of the sialic acid derivative wherein X is oxygen atom and a salt thereof, and a hydrate thereof and a solvate thereof.
- 5 16. The solid dispersion according to any one of claims 1 to 15 wherein the sialic acid derivative is 3 α -[N-(5-acetamido-3,5-dideoxy-2-O-methyl- α -D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestane.
17. The solid dispersion according to any one of claims 1 to 16 which comprises said substance in substantially amorphous state.
- 10 18. A pharmaceutical composition comprising the solid dispersion according to any one of claims 1 to 17 and a pharmaceutically acceptable carrier.

15 **Patentansprüche**

1. Feste Dispersion, die ein wasserlösliches Makromolekül und eine Substanz, die in dem wasserlöslichen Makromolekül dispergiert ist, enthält, wobei diese Substanz ausgewählt ist aus der Gruppe bestehend aus einem Sialinsäurederivat, wiedergegeben durch die folgende allgemeine Formel (I), und einem Salz davon und einem Hydrat davon und einem Solvat davon:
- 20



35 [in der obigen allgemeinen Formel (I) steht R¹ für den Rest einer Steroidverbindung, R² steht für ein Wasserstoffatom oder eine C₁-C₄-Alkylgruppe, R³ steht für eine C₁-C₁₅-Alkylgruppe,




{in der obigen Formel stehen R⁶ und R⁷ unabhängig voneinander für ein Wasserstoffatom, ein Halogenatom, eine C₁-C₄-Alkylgruppe, eine Hydroxylgruppe, R⁸O- (in der Formel steht R⁸ für eine C₁-C₄-Alkylgruppe, eine Phenylgruppe oder eine Phenyl-(C₁-C₃)-alkylgruppe), eine Nitrogruppe, eine Aminogruppe, eine C₁-C₄-Alkylaminogruppe, eine C₂-C₈-Dialkylaminogruppe oder R⁹O-CO- (in der Formel steht R⁹ für ein Wasserstoffatom, eine C₁-C₄-Alkylgruppe, eine Phenylgruppe oder eine Phenyl-(C₁-C₃)-Alkylgruppe) und "L" steht für eine ganze Zahl von 0 bis 6}, R¹⁰O(CH₂)_m- (in der Formel steht R¹⁰ für ein Wasserstoffatom; eine C₁-C₄-Alkylgruppe; eine Phenylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe; oder eine Phenyl-(C₁-C₃)-alkylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe, und das Symbol "m" steht für eine ganze Zahl von 2 bis 6) oder (R¹¹)(R¹²)N-(CH₂)_n- {in der Formel steht R¹¹ für ein Wasserstoffatom oder eine C₁-C₄-Alkylgruppe, R¹² steht für ein Wasserstoffatom; eine C₁-C₄-Alkylgruppe; eine C₂-C₇-Acylgruppe; eine C₁-C₄-Alkylsulfonylgruppe; eine

50

55


Phenylsulfonylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe; oder R¹³O-CO- (in der Formel steht R¹³ für eine C₁-C₄-Alkylgruppe, eine Phenylgruppe oder eine Phenyl-(C₁-C₃)-alkylgruppe) und das Symbol "n" steht für eine ganze Zahl von 2 bis 6}, R⁴ steht für ein Wasserstoffatom oder eine C₂-C₇-Acylgruppe, R⁵ steht für R¹⁴O- (in der Formel steht R¹⁴ für ein Wasserstoffatom oder eine C₂-C₇-Acylgruppe) oder R¹⁵NH- {in der Formel steht R¹⁵ für eine C₂-C₇-Acylgruppe; R¹⁶O (CH₂)_p-CO- (in der Formel steht R¹⁶ für ein Wasserstoffatom, eine C₁-C₆-Alkylgruppe, Phenylgruppe oder eine Phenyl-(C₁-C₃)-alkylgruppe und p steht für eine ganze Zahl von 0 bis 4); eine C₇-C₁₁-Aroylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe; eine Phenyl-(C₁-C₃)-alkylcarbonylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe; eine C₁-C₄-Alkylsulfonylgruppe oder eine Phenylsulfonylgruppe, die einen oder mehrere Substituenten aufweisen kann, ausgewählt aus der Gruppe bestehend aus einer C₁-C₄-Alkylgruppe, einem Halogenatom, einer Hydroxylgruppe, einer Nitrogruppe, einer Aminogruppe und einer Carboxylgruppe} und X steht für ein Sauerstoffatom oder ein Schwefelatom].

2. Die feste Dispersion gemäß Anspruch 1, die die Substanz enthält, die aus der Gruppe ausgewählt ist, bestehend aus dem Sialinsäurederivat, worin R¹ ist:




(in der Formel steht die ---- für eine Einfachbindung oder eine Doppelbindung), und einem Salz davon und einem Hydrat davon und einem Solvat davon.

3. Die feste Dispersion gemäß Anspruch 1, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R¹ ist:




und einem Salz davon und einem Hydrat davon und einem Solvat davon.

4. Feste Dispersion gemäß Anspruch 1, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R¹ ist:



und einem Salz davon und einem Hydrat davon und einem Solvat davon.

- 15
5. Feste Dispersion gemäß einem der Ansprüche 1 bis 4, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R^2 ein Wasserstoffatom oder eine Methylgruppe ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.
- 20
6. Die feste Dispersion gemäß einem der Ansprüche 1 bis 4, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R^2 ein Wasserstoffatom ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.
- 25
7. Feste Dispersion gemäß einem der Ansprüche 1 bis 6, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R^3 eine C_1 - C_8 -Alkylgruppe,




35

{in der Formel stehen R^6 und R^7 unabhängig voneinander für ein Wasserstoffatom, ein Halogenatom, oder R^9O-CO- (in der Formel steht R^9 für ein Wasserstoffatom oder eine C_1 - C_4 -Alkylgruppe) und das Symbol "L" steht für eine ganze Zahl von 0 bis 3}, $R^{10}O(CH_2)_m-$ (in der Formel steht R^{10} für ein Wasserstoffatom, eine C_1 - C_4 -Alkylgruppe, eine Phenylgruppe oder eine Phenyl- (C_1-C_3) -alkylgruppe und das Symbol "m" steht für eine ganze Zahl von 2 bis 4) oder $(R^{11})(R^{12})N-(CH_2)_n-$ {in der Formel steht R^{11} für ein Wasserstoffatom, R^{12} steht für ein Wasserstoffatom, eine C_2 - C_7 -Acylgruppe, eine C_1 - C_4 -Alkylsulfonylgruppe oder $R^{13}O-CO-$ (in der Formel steht R^{13} für eine Phenyl- (C_1-C_3) -alkylgruppe) und das Symbol "n" steht für eine ganze Zahl von 2 bis 4} ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

40

- 45
8. Die feste Dispersion gemäß einem der Ansprüche 1 bis 6, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R^3 eine C_1 - C_8 -Alkylgruppe oder



(in der Formel steht das Symbol "L" für eine ganze Zahl von 0 bis 3) ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

55

9. Feste Dispersion gemäß einem der Ansprüche 1 bis 6, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R^3 eine C_1 - C_3 -Alkylgruppe ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

10. Feste Dispersion gemäß einem der Ansprüche 1 bis 9, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R⁴ ein Wasserstoffatom oder eine Acetylgruppe ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

5 11. Feste Dispersion gemäß einem der Ansprüche 1 bis 9, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R⁴ ein Wasserstoffatom ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

10 12. Feste Dispersion gemäß einem der Ansprüche 1 bis 11, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R⁵ gleich R¹⁴O- (in der Formel steht R¹⁴ für ein Wasserstoffatom oder eine Acetylgruppe) oder R¹⁵- {in der Formel steht R¹⁵ für eine C₂-C₇-Acylgruppe, R¹⁶O(CH₂)_p-CO- (in der Formel steht R¹⁶ für ein Wasserstoffatom, eine C₁-C₄-Alkylgruppe oder eine Phenyl-(C₁-C₃)-alkylgruppe und das Symbol "p" steht für eine ganze Zahl von 0 bis 4), eine C₇-C₁₁-Aroylgruppe, eine C₁-C₃-Alkylsulfonylgruppe oder eine Phenylsulfonylgruppe} ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

15 13. Feste Dispersion gemäß einem der Ansprüche 1 bis 11, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R⁵ gleich R¹⁴O- (in der Formel steht R¹⁴ für ein Wasserstoffatom) oder R¹⁵NH- {in der Formel steht R¹⁵ für eine C₂-C₅-Acylgruppe, R¹⁶O(CH₂)_p-CO- (in der Formel steht R¹⁶ für ein Wasserstoffatom und das Symbol "p" steht für 1)} ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

20 14. Feste Dispersion gemäß einem der Ansprüche 1 bis 11, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin R⁵ gleich R¹⁵NH- (in der Formel steht R¹⁵ für eine Acetylgruppe) ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.

25 15. Feste Dispersion gemäß einem der Ansprüche 1 bis 14, die die Substanz enthält, die ausgewählt ist aus der Gruppe bestehend aus dem Sialinsäurederivat, worin X ein Sauerstoffatom ist, und einem Salz davon und einem Hydrat davon und einem Solvat davon.


30 16. Feste Dispersion gemäß einem der Ansprüche 1 bis 15, worin das Sialinsäurederivat 3α-[N-(5-Acetamido-3,5-dideoxy-2-O-methyl-α-D-glycero-D-galacto-2-nonulopyranosonyl)amino]cholestan ist.

35 17. Feste Dispersion gemäß einem der Ansprüche 1 bis 16, die diese Substanz in einem im Wesentlichen amorphen Zustand enthält.


40 18. Pharmazeutische Zusammensetzung, die die feste Dispersion gemäß einem der Ansprüche 1 bis 17 und einen pharmazeutisch akzeptablen Träger enthält.

40 **Revendications**

1. Dispersion solide qui comprend une macromolécule hydrosoluble et une substance dispersée dans la macromolécule hydrosoluble, dans laquelle ladite substance est choisie dans le groupe constitué par un dérivé d'acide sialique représenté par la formule générale (I) suivante et un sel de celui-ci, et un hydrate et un solvate de celui-ci :



[dans la formule générale (I) ci-dessus, R¹ représente un résidu de composé stéroïdien, R² représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄, R³ représente un groupe alkyle en C₁-C₁₅,



5

10

15

20

25

30


35

{dans la formule, R⁶ et R⁷ représentent indépendamment un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C₁-C₄, un groupe hydroxyle, R⁸O- (dans la formule, R⁸ représente un groupe alkyle en C₁-C₄, un groupe phényle ou un groupe phénylalkyle en C₁-C₈), un groupe nitro, un groupe amino, un groupe alkyl (C₁-C₄) amino, un groupe dialkyl (C₂-C₈) amino ou R⁹O-CO- (dans la formule, R⁹ représente un atome d'hydrogène, un groupe alkyle en C₁-C₄, un groupe phényle ou un groupe phénylalkyle en C₁-C₃), et le symbole « L » représente un nombre entier de 0 à 6}, R¹⁰O(CH₂)_m- (dans la formule, R¹⁰ représente un atome d'hydrogène ; un groupe alkyle en C₁-C₄ ; un groupe phényle qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle ; ou un groupe phénylalkyle en C₁-C₃ qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle, et le symbole « m » représente un nombre entier de 2 à 6), ou (R¹¹)(R¹²)N-(CH₂)_n - (dans la formule, R¹¹ représente un atome d'hydrogène ou un groupe alkyle en C₁-C₄ ; R¹² représente un atome d'hydrogène ; un groupe alkyle en C₁-C₄ ; un groupe acyle en C₂-C₇ ; un groupe alkyl(C₁-C₄)sulfonyl ; un groupe phénylsulfonyl qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle ; ou R¹³O-CO- (dans la formule, R¹³ représente un groupe alkyle en C₁-C₄, un groupe phényle ou un groupe phénylalkyle en C₁-C₃) et le symbole « n » représente un nombre entier de 2 à 6}, R⁴ représente un atome d'hydrogène ou un groupe acyle en C₂-C₇, R⁵ représente R¹⁴O- (dans la formule, R¹⁴ représente un atome d'hydrogène ou un groupe acyle en C₂-C₇) ou R¹⁵NH- (dans la formule, R¹⁵ représente un groupe acyle en C₂-C₇ ; R¹⁶O(CH₂)_p-CO- (dans la formule, R¹⁶ représente un atome d'hydrogène, un groupe alkyle en C₁-C₆, un groupe phényle, ou un groupe phénylalkyle en C₁-C₃), et p représente un nombre entier de 0 à 4) ; un groupe aroyle en C₇-C₁₁ qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle ; un groupe phénylalkyl (C₁-C₃)carbonyl qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle ; un groupe alkyl(C₁-C₄)sulfonyl ; ou un groupe phénylsulfonyl qui peut avoir un ou plusieurs substituants choisis dans le groupe constitué par un groupe alkyle en C₁-C₄, un atome d'halogène, un groupe hydroxyle, un groupe nitro, un groupe amino, et un groupe carboxyle}, et X représente un atome d'oxygène ou un atome de soufre].

2. Dispersion solide selon la revendication 1 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R¹ est :

40

45




50

(dans la formule, représente une liaison simple ou une liaison double) et un sel de celui-ci, et un hydrate et un solvate de celui-ci.

3. Dispersion solide selon la revendication 1 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R¹ est :

55

5




10

et un sel de celui-ci, et un hydrate et un solvate de celui-ci.

4. Dispersion solide selon la revendication 1 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^1 est :

15

20



25

et un sel de celui-ci, et un hydrate et un solvate de celui-ci.

5. Dispersion solide selon l'une quelconque des revendications 1 à 4 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^2 est un atome d'hydrogène ou un groupe méthyle et un sel, et un hydrate et un solvate de celui-ci.


30

6. Dispersion solide selon l'une quelconque des revendications 1 à 4 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^2 est un atome d'hydrogène et un sel, et un hydrate et un solvate de celui-ci.

35

7. Dispersion solide selon l'une quelconque des revendications 1 à 6 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^3 est un groupe alkyle en C_1-C_8 ,

40




45

{dans la formule, R^6 et R^7 représentent indépendamment un atome d'hydrogène, un atome d'halogène, ou R^9O-CO- (dans la formule, R^9 représente un atome d'hydrogène ou un groupe alkyle en C_1-C_4), et le symbole « L » représente un nombre entier de 0 à 3}, $R^{10}O(CH_2)_m-$ (dans la formule, R^{10} représente un atome d'hydrogène, un groupe alkyle en C_1-C_4 , un groupe phényle, ou un groupe phénylalkyle en C_1-C_3 , et le symbole « m » représente un nombre entier de 2 à 4), ou $(R^{11})(R^{12})N-(CH_2)_n-$ {dans la formule, R^{11} représente un atome d'hydrogène, R^{12} représente un atome d'hydrogène, un groupe acyle en C_2-C_7 , un groupe alkyl (C_1-C_4) sulfonyle ou $R^{13}O-CO-$ (dans la formule, R^{13} représente un groupe phénylalkyle en C_1-C_3) et le symbole « n » représente un nombre entier de 2 à 4} et un sel de celui-ci, et un hydrate et un solvate de celui-ci.

50

55

8. Dispersion solide selon l'une quelconque des revendications 1 à 6 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^3 est un groupe alkyle en C_1-C_8 ou



5

(dans la formule, le symbole « L » représente un nombre entier de 0 à 3), et un sel de celui-ci, et un hydrate et un solvate de celui-ci.

- 10 **9.** Dispersion solide selon l'une quelconque des revendications 1 à 6 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^3 est un groupe alkyle en C_1-C_3 et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 15 **10.** Dispersion solide selon l'une quelconque des revendications 1 à 9 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^4 est un atome d'hydrogène ou un groupe acétyle et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 20 **11.** Dispersion solide selon l'une quelconque des revendications 1 à 9 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^4 est un atome d'hydrogène et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 25 **12.** Dispersion solide selon l'une quelconque des revendications 1 à 11 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^5 est $R^{14}O-$ (dans la formule, R^{14} représente un atome d'hydrogène ou un groupe acétyle) ou $R^{15}NH-$ (dans la formule, R^{15} représente un groupe acyle en C_2-C_7 , $R^{16}O(CH_2)_p-CO-$ (dans la formule, R^{16} représente un atome d'hydrogène, un groupe alkyle en C_1-C_4 ou un groupe phénylalkyle en C_1-C_3 , et le symbole « p » représente un nombre entier de 0 à 4), un groupe aroyle en C_7-C_{11} , un groupe alkyl (C_1-C_3) sulfonyle ou un groupe phénylsulfonyl} et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 30 **13.** Dispersion solide selon l'une quelconque des revendications 1 à 11 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^5 est $R^{14}O-$ (dans la formule, R^{14} représente un atome d'hydrogène) ou $R^{15}NH-$ {dans la formule, R^{15} représente un groupe acyle en C_2-C_5 , $R^{16}O(CH_2)_p-CO-$ (dans la formule, R^{16} représente un atome d'hydrogène et le symbole « p » représente 1)} et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 35 **14.** Dispersion solide selon l'une quelconque des revendications 1 à 11 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel R^5 est $R^{15}NH-$ (dans la formule, R^{15} représente un groupe acétyle) et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 40 **15.** Dispersion solide selon l'une quelconque des revendications 1 à 14 qui comprend la substance choisie dans le groupe constitué par le dérivé d'acide sialique, dans lequel X est un atome d'oxygène et un sel de celui-ci, et un hydrate et un solvate de celui-ci.
- 45 **16.** Dispersion solide selon l'une quelconque des revendications 1 à 15 dans laquelle le dérivé d'acide sialique est un 3α -[N-(5-acétamido-3,5-didésoxy-2-O-méthyl- α -D-glycéro-D-galacto-2-nonulopyranosonyl)amino]cholestane.
- 17.** Dispersion solide selon l'une quelconque des revendications 1 à 16 qui comprend ladite substance à l'état essentiellement amorphe.
- 50 **18.** Composition pharmaceutique comprenant la dispersion solide selon l'une quelconque des revendications 1 à 17 et un véhicule pharmaceutiquement acceptable.

55

Fig. 1




Fig. 2





Fig. 3



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 58778111983 B [0003]
- JP 55892981980 B [0004]
- JP 612430961986 B [0004]
- JP 612823901986 B [0004]
- JP 63414921988 B [0004]
- JP 63414941988 B [0004]
- JP 63636971988 B [0004]
- JP 63685261988 B [0004]
- JP 64527941989 B [0004]
- JP 11906931989 B [0004]
- JP 31513981991 B [0004]
- WO 9310134 A [0004]
- WO 9403469 A [0004]
- JP 622652291987 B [0004]
- JP 1193529 A [0004]
- JP 3377898 A [0004]
- JP 3381287 A [0004]
- JP 72285921995 B [0005] [0006] [0019] [0020] [0023]

Non-patent literature cited in the description

- *Chem. Pharm. Bull.*, 1986, vol. 34 (8), 3408 [0003]
- *J. Pharm. Sci.*, 1970, vol. 59, 937 [0003] [0025]
- *Yakuzaigaku*, 1985, vol. 45 (4), 291 [0003] [0025]
- *Chem. Pharm. Bull.*, 1996, vol. 44 (3), 568 [0003] [0025]
- *Brain Research*, 1988, vol. 438, 277-285 [0004]
- *Chem. Pharm. Bull.*, 1986, vol. 34 (8), 348 [0025]